BackLiminatus Pharma Class A Common Stock Overview

Liminatus Pharma Class A Common Stock Other Current Assets

Liminatus Pharma Class A Common Stock's other current assets is $380K.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$375371.00
↓ 15.47% YoYΔ $-68715.00 vs prior year quarter

Peer average / median

Loading

Liminatus Pharma Class A Common Stock Other Current Assets History

Loading

Liminatus Pharma Class A Common Stock vs. peers: Other Current Assets Comparison

Loading

Liminatus Pharma Class A Common Stock Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Liminatus Pharma Class A Common Stock (LIMN) FAQ

The latest other current assets for LIMN is $380K as of June 2026. That compares with $440K in the prior-year period — down 15.5% year over year. Investors often review this figure alongside Liminatus Pharma Class A Common Stock's historical trend and sector peers before judging valuation or financial health.

Over the past year, LIMN's other current assets moved from $440K to $380K — a 15.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Liminatus Pharma Class A Common Stock's operating scale or balance-sheet position.

A other current assets figure of $380K for LIMN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LIMN's other current assets ($380K), review year-over-year change from $440K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.